Review Article

Targeting Gonadotropins: An Alternative Option for Alzheimer Disease Treatment

Gemma Casadesus,1 Emma Ramiro Puig,2 Kate M. Webber,1 Craig S. Atwood,3 Margarida Castell Escuer,2 Richard L. Bowen,4 George Perry,1 and Mark A. Smith 1

1 Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA
2 Departament de Fisiologia, Facultat de Farmacia, Universitat de Barcelona, Barcelona 08028, Spain
3 School of Medicine, University of Wisconsin and William S. Middleton Memorial Veterans Administration, Madison, WI 53705, USA
4 Voyager Pharmaceutical Corporation, Raleigh, NC 27615, USA

Received 5 January 2006; Revised 10 May 2006; Accepted 28 June 2006

Recent evidence indicates that, alongside oxidative stress, dysregulation of the cell cycle in neurons susceptible to degeneration in Alzheimer disease may play a crucial role in the initiation of the disease. As such, the role of reproductive hormones, which are closely associated with the cell cycle both during development and after birth, may be of key importance. While estrogen has been the primary focus, the protective effects of hormone replacement therapy on cognition and dementia only during a "crucial period" led us to expand the study of hormonal influences to other members of the hypothalamic pituitary axis. Specifically, in this review, we focus on luteinizing hormone, which is not only increased in the sera of patients with Alzheimer disease but, like estrogen, is modulated by hormone replacement therapy and also influences cognitive behavior and pathogenic processing in animal models of the disease. Targeting gonadotropins may be a useful treatment strategy for disease targeting multiple pleiotropic downstream consequences.

BACKGROUND: ALZHEIMER’S DISEASE

Alzheimer’s disease (AD), the primarily cause of senile dementia, is characterized by progressive memory loss, impairments in language and visual-spatial skills, episodes of psychosis, aggressiveness, and agitation, and ultimately death (reviewed in [1, 2]). AD is the most prevalent neurodegenerative disease, affecting approximately 4-5 million people in the United States and 15 million people worldwide. Given current population demographic predictions, it is estimated that by 2050, 50 million people will suffer from this devastating disease if no successful treatments are found [3]. The severity and the chronicity of this disease ultimately leads to institutionalization of patients, and thus results in a tremendous cost for the individual families and for society at large. Indeed, in the United States alone, the current cost of caring for patients with AD dementia is estimated at $100 billion per year and this will undoubtedly increase in coming years [4].

Unfortunately, to date, only palliative treatments of the symptoms are available and it is widely accepted that a better understanding of the etiology and disease pathogenesis is crucial for the development of new drugs capable of forestalling the progression of the disease. The leading hypothesis, the amyloid-β hypothesis, which is based on mutations in either the amyloid-β protein precursor (AβPP) or presenilins-1/2 (PSEN1/2) that affect the processing of amyloid-β and contribute to its accumulation in neurons and consequent formation of senile plaques [5], has come under increased scrutiny since manipulation of amyloid-β in cell or animal models does not yield the multitude of biochemical and cellular changes characteristic of the human disease. In fact, it is becoming increasingly evident that amyloid-β deposition may be a consequence rather than an initiator of the pathophysiological cascade [6–9]. Other mechanisms of disease, such as abnormally hyperphosphorylated bundles of tau protein found in neurofibrillary tangles [10], oxidative stress [11], metal ion deregulation [12],
and inflammation [13] also fail to completely explain all the abnormalities found in AD. Moreover, the lack of efficient therapeutic strategies based on such mechanisms only serves to emphasize the fundamental gap in our knowledge of disease.

**CELL CYCLE DYSREGULATION: AN ALTERNATIVE HYPOTHESIS FOR ALZHEIMER’S DISEASE**

There is increasing evidence for activated cell cycle in the vulnerable neuronal population in AD [14–16]. We suspect that the dysregulation of the cell cycle, in conjunction with oxidative stress, in hippocampal neurons leads to initiation of the pathophysiological cascade of AD [17]. This hypothesis is supported by several neuronal changes seen in AD including the ectopic expression of markers of cell cycle [18], organelle kinesis [19], and cytoskeletal alterations such as tau phosphorylation [20]. Importantly, and suggestive of this pivotal effect, mitotic alterations are not only one of the earliest neuronal abnormalities found in AD but are also related to the majority of the pathological hallmarks, such as hyperphosphorylation of tau, amyloid-β accumulation, and oxidative stress (reviewed in [21]). To this end, a near identical phosphorylation of tau also occur when cells are mitotically active and phosphorylation is driven by cyclin-dependent kinases (CDKs) [22–25]. Therefore, one possibility is that cell cycle alterations could lead to tau phosphorylation and subsequent neuronal degeneration. In support of this hypothesis, several reports in the literature indicate that cell cycle markers are abnormally expressed in nerve cells with filamentous tau deposits. These markers include proteins cyclin D and Cdk4/Cdk6, involved in the G0/G1 transition, retinoblastoma protein, and the Cdk inhibitors p15, p16, p18, and p19 [26–32]. Other markers such as cyclin E and Cdc25A, usually associated with G1/S transition, have also been shown to be abnormally expressed in degenerating neurons [33–35]. Importantly, colocalization of different cell cycle markers with phosphorylated tau protein has also been demonstrated. In this regard, colocalization of cyclin B, Cdc2, Cdc25B, Polo-like kinase, Mwt1/Wee1, and p27Kip1, all regulators of the G2/M transition, and some mitotic epitopes, such as phosphorylated histone H3, phosphorylated RNA polymerase II, PCNA, Ki67, and MPM2, has been demonstrated [27, 33, 34, 36–45]. Importantly some of these markers appear to precede the phosphorylation and aggregation of tau protein, suggesting a possible cause-and-effect relationship [37, 46, 47]. Moreover, these in vivo findings are supported by studies in cell models showing AD-like phosphorylation of tau protein in mitotically active cells [48–50] and also by the phosphorylation of recombinant tau by CDKs in vitro [51]. While cell cycle changes often precede tau phosphorylation, in a Drosophila model, cell cycle abnormalities appear to follow tau alterations [52]. Also, of relevance, experimental studies have established that inappropriate reentry into the cell cycle results in nerve cell death and reactivation of the cell-cycle machinery likely plays an important role in the apoptotic death of postmitotic neurons [53, 54]. Taken together, these findings indicate that cell cycle is intimately associated with AD and tau phosphorylation. However, as stated above, the chronology and mechanistic origin of tau phosphorylation remain to be clearly characterized.

There is also abundant evidence indicating that oxidative stress and free radical damage play key roles in the pathogenesis of AD [11, 55, 56]. Importantly free radicals, free-radical generators, and antioxidants act as crucial control parameters of the cell cycle [57] and have all been implicated in the development or halting of cell-cycle-related diseases such as cancer [58]. Therefore, one possibility is that oxidative stress and cell cycle dysregulation work synergistically in the development of AD [59]. In support of this notion, during the cell cycle, there is division and redistribution of cellular organelles such that mitochondrial proliferation is evident [60]. Mitochondrial proliferation is imperative for providing the energy needed for cell division, however, in cells where the cell cycle is interrupted or dysfunctional, cells incur a “phase stasis” to serve as a potent source of free radicals and cause redox imbalance [6], especially in those redox reactions involving calcium metabolism [61]. On the other hand, it is known that one pathway for oxidative stress mediated neuronal cell death is cell cycle reentry [62] and antioxidant treatments, most with potent cell-cycle inhibitory properties produce declines in tau phosphorylation [63]. Therapeutic interventions specifically designed to arrest cells at G0 phase of the cell cycle, halt mitotic signalling cascades, or reduce the levels of endogenous or exogenous mitogens responsible for the aberrant mitosis in senescent neurons could have a tremendous success in AD treatment (reviewed in [21, 64]). Supporting this, nonsteroidal anti-inflammatory drugs (NSAIDs), which also possess antiproliferative properties, are useful to delay the progression of AD [65]. Likewise, antiapoptotic compounds such as resveratrol are well established in aging and AD. Resveratrol, a potent antioxidant of natural origin [66–69], may be of benefit in murine senescence and AD models and in some clinical studies in patients with AD [70]. Studies with animals also demonstrated protective effects of resveratrol against kainate-induced seizures [71] and its protective effects against brain injury due to ischemia/reperfusion in gerbil model [72]. Likewise, flavopiridol, a synthetic flavone closely related to a compound found in a plant native to India, Dysoxylum binectariferum, is a potent inhibitor of most CDKs, including CDK1, CDK2, CDK4, and CDK7 [73]. It induces growth arrest at either the G1 and/or G2 phases of the cell cycle in numerous cell lines in vitro by acting as a competitive binding agent for the ATP-binding pocket of CDK [73]. One consequence of this inhibition is a decrease in cyclin D1, the binding partner of CDK4 in G1, by depletion of cyclin D1 mRNA resulting in a decrease in CDK4 kinase activity [74]. Importantly, the drug is in phase I and II clinical trials as an antineoplastic agent for breast, gastric, and renal cancers [75] and recent studies demonstrate its effectiveness on brain cancers such as gliomas [76]. These findings indicate that flavopiridol is a powerful CDK inhibitor as well as a potential therapeutic avenue for AD.
Notably, one powerful endogenous mitogen, luteinizing hormone (LH), a gonadotropin most often associated with reproduction, is particularly increased during aging and AD. Therefore another potential therapeutic option is to target age-related increases of this hormone in AD. The exploration of the link between gonadotropins such as LH and the etiology of AD and its potential value as a therapeutic avenue will be the focus of this review.

ARE SEX STEROIDS INVOLVED IN THE ETIOLOGY OF ALZHEIMER’S DISEASE?

Hormones of the hypothalamic-pituitary-gonadal (HPG) axis include gonadotropin releasing hormone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen, progesterone, testosterone, activin, inhibin, and follistatin. Each of these hormones is involved in regulating reproductive function by participating in a complex feedback loop. Briefly, this loop is initiated by the secretion of hypothalamic gonadotropin releasing hormone that stimulates the pituitary to secrete the gonadotropins LH and FSH. These gonadotropins are capable of stimulating oogenesis/spermatogenesis as well as the production of sex steroids which complete the feedback loop by reducing the gonadotropin secretion by the hypothalamus into the bloodstream [77].

Menopause and andropause are characterized by a dramatic decline in sex steroids resulting in an increase in the production of gonadotropins. To this end, in women, gonadotropins are considerably increased reaching a 3- to 4-fold increase in the concentration of serum LH and a 4- to 18-fold increase in FSH. Men also experience an increase of LH and FSH, but to a lower degree than in women, resulting only in a 2-fold and 3-fold increase, respectively [78, 79]. Notably, the link between the HPG axis hormones and AD is not new as it has been hypothesized that the marked reduction in sex hormone levels during postmenopausal states results in various physiological and psychological changes associated with the development and progression of AD. In this regard, several epidemiological studies indicate that women have a higher predisposition to develop AD than do men [80–82] and treatment with hormone replacement therapy (HRT) reduced this risk in women [83, 84]. These gender differences, in addition to the capacity of HRT to reduce this risk in postmenopausal women, led researchers to investigate the role of female sex steroids, namely, estrogen, in the pathogenesis of AD.

To this end, estrogen can act as a neuroprotective agent by lowering the brain levels of amyloid-β [85], by ameliorating the nerve cell injury caused by amyloid-β [86], and/or promoting synaptic plasticity and growth of nerve processes [87]. Moreover, estrogen is also capable of reducing oxidative stress, increasing cerebral blood flow, and enhancing cholinergic function and glucose transport into the brain [88]. All of these effects have a well-known positive impact on the prevention and the amelioration of AD. However, recent prospective studies, including the Women’s Health Initiative Memory Study (WHIMS), seem to contradict the previous promising observations regarding HRT. WHIMS, a randomized clinical trial designed to assess the incidence of dementia among relatively healthy postmenopausal women under HRT, showed a substantially increased overall incidence of dementia in postmenopausal women [89–91]. Since hormone therapy is relatively common for menopausal women, these latter findings have raised serious concerns about the long term efficacy and safety of HRT.

HORMONE REPLACEMENT: TIMING IS EVERYTHING

Many hypotheses have been postulated to justify the results of the WHIMS. To date, some aspects related to the form (estriadiol versus conjugated equine estrogen (CEE)) and the route of administration (oral versus transdermal) of estrogen, the choice of progestin (natural versus synthetic progestins), the high doses administered, the type of treatment regimen (continuous versus cyclic) might be important points to be considered (reviewed in [92, 93]). For instance, the adverse effects on cognition are mainly attributed to the thromboembolic complications of oral CEE [94]. However, one aspect that has been overlooked and that is tightly linked to the timing of hormone therapy (ie, perimenopausal versus postmenopausal) is the release of, and capacity of, HRT to lower gonadotropins such as LH. In fact, it is only when one takes into account the role of these other hormones of the hypothalamic-pituitary-gonadal axis (reviewed in [77]), during a “critical period” around the onset of menopause and the years beyond that cognitive decline and susceptibility, onset, and progression of AD can be accurately characterized. To this end, chronic elevation of gonadotropins and decline in sex steroids leads to HPG axis shutdown. Therefore, HRT started in older women such as those of the WHIMS [89], while bringing estrogen to premenopausal levels, cannot decrease the levels of gonadotropins such as LH. On the other hand, HRT started during perimenopause or early menopause, when the HPG axis feedback loop system is functional, does lead to a lowering of LH. Supporting this hypothesis, the levels of gonadotropins including LH are highest during peri-menopause and early menopause [95], when HRT has been observed to be most successful in preventing dementia [96, 97]. Likewise, studies also demonstrate that while cognitive decline can be rescued with estrogen therapy initiated immediately after menopause and ovariectomy (mimics menopause), however, unless subjects are previously primed with estrogen [98], estrogen replacement initiated after a long interval following menopause or ovariectomy is ineffective at rescuing cognition [99–101]. This later finding suggests that by priming, HPG-axis functionality is sustained and thus led to cognitive improvements after HRT. Likewise, estrogen becomes increasingly less effective at modulating LH expression and biosynthesis the longer that HRT is started after ovariectomy [102], a mechanism that is specifically mediated by the gonadotropin-releasing hormone (GnRH) receptor [103, 104]. Importantly, the ovariectomy findings parallel those observed during aging, such that estrogen feedback on LH secretion [105] and GnRH gene expression [106] is decreased. Whether
the beneficial AND detrimental effects of HRT are associated with menopause-driven gonadotropin changes is not yet fully known and is currently being examined in our laboratory. However, the above-cited evidence does indicate that timing, pituitary function, and estrogen-gonadotropin influences are more complex than previously thought. These findings may provide the reconciliating link between the contradicting data presented in the WHIMS and prior observational/epidemiological studies. Moreover, these data suggest a potential role for gonadotropins in the CNS, particularly on cognitive decline and AD pathogenesis and, more importantly, places gonadotropins as a potential therapeutic target for the treatment of AD.

EVIDENCE FOR A ROLE OF LH IN ALZHEIMER’S DISEASE

Epidemiological data supports a role of LH in AD. In this regard, and paralleling the female predominance for developing AD [81, 82, 107, 108], LH levels are significantly higher in females compared to males [97] and LH levels are higher still in individuals who succumb to AD [109, 110]. Also important is the fact that, in Down syndrome, where the prevalence of AD-like etiology is higher in males than in females, that is, a reversal to what is observed in the normal population, males have higher serum LH levels compared to females [111, 112]. Therefore, LH allows an explanation for the reversal of the classical gender-predisposition in AD versus Down syndrome [113].

Like epidemiological data, direct experimental evidence also indicates that LH may be an important player in the development and progression of AD. In this regard, LH is capable of modulating cognitive behavior [114], is present in the brain, and has the highest levels of its receptor in the hippocampus [115], a key processor of cognition affected by aging and severely deteriorated in AD. Furthermore, we have recently examined cognitive function in a well-characterized transgenic line that overexpresses LH [116–118] and have found that these animals show decreased cognitive performance when compared to controls [119]. Since other hormones in addition to LH are altered in the LH overexpressing mice, we also measured Y-maze performance in a well-characterized LH receptor knockout (LHRKO) strain of mice [120], which also have very high levels of LH, to begin to determine whether cognitive decline could be mediated by a specific LH mechanism (ie, the LH receptor). In this regard, LHRKO (+/-) mice performed indistinguishable from wild-type (+/+). Therefore, the negative effects on cognition affected by high levels of LH were completely attenuated by knockout of the receptor. While comparing the TgLH-β and LHRKO animals should be done with caution (ie, different strain and background), changes in estrogen levels were unlikely to be responsible for the cognitive changes observed in this study since LH overexpressers show elevated rather than diminished levels of estrogen [116–118] and LHRKO mice show decreased levels of estrogen when compared to wild-type littermate controls [120]. On the other hand, both do show high LH but this is obviously a nonissue in the LHRKO animals. These findings support our hypothesis that modulation of cognition by estrogen is interrelated with the status of LH levels and function. Finally, recently we also found that experimentally abolishing LH in the AβPP transgenic mouse, an animal model of AD, using a selective GnRH agonist (leuprolide acetate) that has been shown to reduce LH to undetectable levels by downregulating the pituitary gonadotropin-releasing hormone receptors [121, 122], improved hippocampally related cognitive performance and decreased amyloid-β deposition in these mice when compared to aged-matched controls [123]. These findings, together with data indicating that LH modulates AβPP processing in vivo and in vitro [122], suggest that LH may be a key player in this disease.

Mechanistically, and as alluded to in the previous section, LH could be working via the modulation of cell cycle. LH is known to be a potent mitogen [124, 125] by acting through MAP kinases pathway [126]. In this regard, LH activates ERK [127] and other transcription factors [128] all involved in cell cycle [129], thus suggesting that high levels of this hormone could lead to the aberrant cell cycle reentry of neurons observed in AD.

CAN TARGETING LH BE THE NEW THERAPEUTIC AVENUE?

Findings discussed in this review indicate that targeting the release of LH may indeed be a successful strategy to prevent and forestall the progression of AD. As discussed above, preclinical data using leuprolide acetate leads to modulation of AβPP processing in normal mice [122] and cognitive improvement and decreased amyloid-β burden in AβPP transgenic mice [123]. More importantly, a recently completed phase II clinical trial shows stabilization in cognitive decline in a subgroup of AD patients treated with leuprolide acetate (http://clinicaltrials.gov/ct/show/nct00076440?orden=6). Specifically, female AD patients treated with high doses of leuprolide acetate (http://www.secinfo.com/d14D5a.z6483. htp, pages 56–64) showed stabilization in cognitive function and activities of daily living. These promising findings support the importance of LH in AD and give way for an alternative and much needed therapeutic avenue for this insidious disease.

REFERENCES

[1] Smith MA. Alzheimer disease. International Review of Neurobiology. 1998:42:1–54.
[2] Robert PH, Verhey FRJ, Byrne EJ, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. European Psychiatry. 2005;20(7):490–496.
[3] Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Archives of Neurology. 2003;60(8):1119–1122.
[4] Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. American Journal Geriatric Pharmacotherapy. 2005;3(1):39–49.
[5] Perry G, Nunomura A, Raina AK, Smith MA. Amyloid-β junks. *Lancet*. 2000;355(9205):757.

[6] Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*. 2001;60(8):759–767.

[7] Rottkamp CA, Atwood CS, Joseph JA, Nunomura A, Perry G, Smith MA. The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease. *Peptides*. 2002;23(7):1333–1341.

[8] Takeuchi A, Irizarry MC, Duff K, et al. Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. *American Journal of Pathology*. 2000;157(1):331–339.

[9] Irizarry MC, Soriano F, McNamara M, et al. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. *Journal of Neuroscience*. 1997;17(18):7053–7059.

[10] Trojanowski JQ, Clark CM, Araujo H, Lee VM-Y. Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer’s disease. *Journal of Alzheimer’s Disease*. 1999;1(4-5):297–305.

[11] Perry G, Castellani RI, Hirai K, Smith MA. Reactive oxygen species mediate cellular damage in Alzheimer disease. *Journal of Alzheimer’s Disease*. 1998;1(1):45–55.

[12] Perry G, Sayre LM, Atwood CS, et al. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. *CNS Drugs*. 2002;16(5):339–352.

[13] Atwood CS, Huang X, Moir RD, et al. Neuroinflammatory responses in the Alzheimer’s disease brain promote the oxidative post-translation modification of amyloid deposits. In: Iqbal K, Sisodia SS, Winblad B, eds. *Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics*. Chichester, UK: John Wiley & Sons; 2001:341–361.

[14] Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A. Cyclin-β2 towards dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. *Journal of Neuroscience Research*. 2000;61(2):128–133.

[15] Copani A, Condorelli F, Canonico PL, Nicoletti F, Sortino MA. Cell cycle progression towards Alzheimer’s disease. *Functional Neurology*. 2001;16(4):11–15.

[16] Arendt T. Dysregulation of neuronal differentiation and cell cycle control in Alzheimer’s disease. *Journal of Neural Transmission. Supplement*. 2002;62:77–85.

[17] Zhu X, Webber KM, Casadesus G, et al. Mitotic and gender parallels in Alzheimer disease: therapeutic opportunities. *Current Drug Targets*. 2004;5(6):559–563.

[18] Bowser R, Smith MA. Cell cycle proteins in Alzheimer’s disease: plenty of wheels but no cycle. *Journal of Alzheimer’s Disease*. 2002;4(3):249–254.

[19] Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer’s disease. *Journal of Neuroscience*. 2001;21(9):3017–3023.

[20] Zhu X, Raina AK, Boux H, Simmons ZL, Takeda A, Smith MA. Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. *International Journal of Developmental Neuroscience*. 2000;18(4-5):433–437.

[21] Webber KM, Bowen RL, Casadesus G, Perry G, Atwood CS, Smith MA. Gonadotropins and Alzheimer’s disease: the link between estrogen replacement therapy and neuroprotection. *Acta Neurobiologica Experimentalis*. 2004;64(1):113–118.

[22] Kanemaru K, Takio K, Miura R, Titani K, Ihara Y. Fetal-type phosphorylation of the tau in paired helical filaments. *Journal of Neurochemistry*. 1992;58(5):1667–1675.

[23] Goedert M, Jakes R, Crowther RA, et al. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. *Proceedings of the National Academy of Sciences of the United States of America*. 1993;90(11):5066–5070.

[24] Brion J-P, Octave JN, Couck AM. Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. *Neuroscience*. 1994;63(3):895–909.

[25] Brion J-P, Couck A-M. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin- dependent kinase 5. *American Journal of Pathology*. 1995;147(5):1465–1476.

[26] Arendt T, Rödel L, Gärtner U, Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer’s disease. *NeuroReport*. 1996;7(18):3047–3049.

[27] McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators p16 and CDK4 in Alzheimer’s disease. *American Journal of Pathology*. 1997;150(6):1933–1939.

[28] Arendt T, Holzer M, Gärtner U. Neuronal expression of cyclin-dependent kinase inhibitors of the INK4 family in Alzheimer’s disease. *Journal of Neural Transmission*. 1998;105(8-9):949–960.

[29] Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer’s disease brain. *Journal of Neuroscience*. 1998;18(8):2801–2807.

[30] Jordan-Sciutto KL, Malaiyandi LM, Bowser R. Altered distribution of cell cycle transcriptional regulators during Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*. 2002;61(4):358–367.

[31] Tsujio Y, Takahashi M, Tsuboi Y, Yamamoto T, Yamada T. Localization and expression of cdc2 and cdk4 in Alzheimer brain tissue. *Dementia and Geriatric Cognitive Disorders*. 1999;10(3):192–198.

[32] Hoozemans JJM, Brückner MK, Rozenmuller AJM, Veerhuis R, Eikelenboom P, Arendt T. Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. *Journal of Neuropathology and Experimental Neurology*. 2002;61(8):678–688.

[33] Nagy Z, Esiri MM, Smith AD. Expression of cell division markers in the hippocampus in Alzheimer’s disease and other neurodegenerative conditions. *Acta Neuropathologica*. 1997;93(3):294–300.

[34] Nagy Z, Esiri MM, Cato A-M, Smith AD. Cell cycle markers in the hippocampus in Alzheimer disease. *Acta Neuropathologica*. 1997;94(1):6–15.

[35] Ding X-L, Husseman J, Tomashevski A, Nochlin D, Jin L-W, Vincent I. The cell cycle Cdc25A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer’s disease. *Journal of Neuroscience*. 2001;21(9):3017–3023.

[36] Webber KM, Bowen RL, Casadesus G, Perry G, Atwood CS, Smith MA. Gonadotropins and Alzheimer’s disease: the link between estrogen replacement therapy and neuroprotection. *Acta Neurobiologica Experimentalis*. 2004;64(1):113–118.
[75] Dobashi Y, Takehana T, Ooi A. Perspectives on cancer therapy: cell cycle blockers and perturbators. Current Medicinal Chemistry. 2003;10(23):2549–2558.

[76] Newcomb EW, Tamasdan C, Entzinger Y, et al. Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy. Cell Cycle. 2004;3(2):230–234.

[77] Genazzani AR, Gastaldi M, Bidzinska B, et al. The brain as a target organ of gonadal steroids. Psychoneuroendocrinology. 1992;17(4):385–390.

[78] Wête C, Sidis Y, Keutmann H, Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Experimental Biology and Medicine. 2002;227(9):724–752.

[79] Couzinnet B, Schaison G. The control of gonadotrophin secretion by ovarian steroids. Human Reproduction. 1993;8(suppl 2):97–101.

[80] Letcher L, Commenges D, Dartigues JF, Barberger-Gateau P. Incidence of dementia and Alzheimer’s disease in elderly community residents of south-western France. International Journal of Epidemiology. 1994;23(6):1256–1261.

[81] Breitner JCS, Silverman JM, Mohs RC, Davis KL. Familial aggregation in Alzheimer’s disease: comparison of risk among relatives of early- and late-onset cases, and among male and female relatives in successive generations. Neurology. 1988;38(2):207–212.

[82] Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Annals of Neurology. 1991;30(3):381–390.

[83] Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. Journal of the American Medical Association. 1998;279(9):688–695.

[84] Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonad hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101(3):485–512.

[85] Petanceska SS, Nagy V, Frail D, Gandy S. Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Annals of the New York Academy of Sciences. 2005;1052:93–115.

[86] Baun LW, Sex, hormones, and Alzheimer’s disease. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(6):736–743.

[87] Yaffe K. Hormone therapy and the brain: Déjà vu all over again? Journal of the American Medical Association. 2003;289(20):2717–2719.

[88] Burger HG. The endocrinology of the menopause. Maturitas. 1996;23(2):129–136.

[89] Henderson VW. Hormone therapy and Alzheimer’s disease: benefit or harm? Expert Opinion on Pharmacotherapy. 2004;5(2):389–406.

[90] Zandi PP, Marcus MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County study. Journal of the American Medical Association. 2002;288(17):2123–2129.

[91] Markowska AL, Savonenko AV. Effectiveness of estrogen replacement in restoration of cognitive function after long-term estrogen withdrawal in aging rats. Journal of Neuroscience. 2002;22(24):10985–10995.

[92] Gibbs RB. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiology of Aging. 2000;21(1):107–116.

[93] Sherwin BB. Estrogen and memory in women: how can we reconcile the findings? Hormones and Behavior. 2005;47(3):371–375.

[94] Daniel JM, Hulst JL, Berbling JL. Estradiol replacement enhances working memory in middle-aged rats when initiated immediately after ovariectomy but not after a long-term period of ovarian hormone deprivation. Endocrinology. 2006;147(1):607–614.

[95] King JC, Anthony EL, Damassa DA, Elkind-Hirsch KE. Morphological evidence that luteinizing hormone-releasing hormone neurons participate in the suppression by estradiol of pituitary luteinizing hormone secretion in ovariectomized rats. Neuroendocrinology. 1987;45(1):1–13.

[96] Tsai HW, Legan SJ. Loss of luteinizing hormone surges induced by chronic estradiol is associated with decreased activation of gonadotropin-releasing hormone neurons. Biology of Reproduction. 2002;66(4):1104–1110.

[97] Dalkin AC, Haisenleder DJ, Ortolano GA, Suhr A, Marshall JC. Gonadal regulation of gonadotropin subunit gene expression: evidence for regulation of follicle-stimulating hormone-β messenger ribonucleic acid by nonsteroidal hormones in female rats. Endocrinology. 1990;127(2):798–806.

[98] Lloyd JM, Hoffman GE, Wise PM. Decline in immediate early gene expression in gonadotropin-releasing hormone neurons during proestrus in regularly cycling, middle-aged rats. Endocrinology. 1994;134(4):1800–1803.

[99] Park OK, Gugneja S, Mayo KE. Gonadotropin-releasing hormone gene expression during the rat estrous cycle: effects of pentobarbital and ovarian steroids. Endocrinology. 1990;127(1):365–372.
